Tom Spurling – Executive Director – Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
Copyright 2023 – Finance News Network
Source: Finance News Network
02 Jun 2022 - BluGlass Limited (ASX:BLG) Executive Chair James Walker provides an update on the company, discussing new staff and developments at BluGlass' manufacturing facility in Silicon Valley.
Read More18 Feb 2021 - QEM Limited (ASX:QEM) Managing Director, Gavin Loyden provides an update on the company's flagship Julia Creek vanadium and oil shale project in North Western Queensland, including work on the optimal processing route and the appointment of UK-based engineering consultancy GSA Environmental Limited (GSAe) to conduct vanadium extraction test work on Julia Creek shale.
Read More11 Aug 2025 - Inside Etherstack’s multi-year partnership with the world’s largest telecom
Read More27 May 2021 - Next Science Limited (ASX:NXS) Founder and Chief Technology Officer Dr Matthew Myntti talks about the problem of biofilms, Next Science's antimicrobial treatments and the company's recent FDA approval.
Read More20 Nov 2023 - Dotz Nano (ASX:DTZ) navigates global challenges, focusing on carbon capture tech after strategic acquisitions and collaborations. CEO Sharon Malka discusses their resilient approach and plans for growth.
Read More09 Dec 2020 - Alterity Therapeutics Limited (ASX:ATH) Chairman and CEO Geoffrey Kempler provides an update on the company's lead compound ATH434 for Multiple System Atrophy, its dual strategy in Europe and the US and its Phase 2 plans.
Read More28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
Read More06 Sep 2019 - Argo Investments Limited (ASX:ARG) Managing Director, Jason Beddow talks about the Listed Investment Company’s performance, record low interest rates and finding long-term value.
Read More11 Dec 2024 - INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
Read More19 Mar 2024 - Torque Metals Limited (ASX:TOR) Managing Director Cristian Moreno discusses the roadmap for the company and promising recent results.
Read More
